Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel

Grant, Justin; Blicker, M.; Piquette-Miller, Micheline; Allen, Christine

doi:10.1002/jps.20379

Cited by 68 publications

(63 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ionic and hydrogen bonding interactions of chitosan and PC may be explained by the high tensile strength and elongation of PC1Cs2 compared to NPC/Cs2 and since chitosan provides film forming property in these formulations, the higher strength and elasticity of PC1Cs2 compared to PC2Cs2 could be because of higher ratio of chitosan to PC in this formulation. Presence of drug crystals may be the reason for brittleness and lower TS and EB of NPC/Cs2 as well (3,10,24).…”

Section: Discussionmentioning

confidence: 99%

“…W 2 is the weight of film at each time point and W 1 is the weight of initial dry film (3). Then the samples were desiccated in an oven at 60°C for 24 hours and the weights of dried films (W 3 ) were recorded.…”

Section: Swelling and Erosionmentioning

confidence: 99%

“…The film forming property of chitosan has made it interesting for transdermal/ dermal drug delivery (2). Due to the hydrophilic nature of chitosan, films composed of chitosan alone showed lack of stability, chemical cross linking with agents such as glutaraldehyde could overcome this, but they have been found to be toxic and the films are often non-biodegradable (3). Blending chitosan with other materials to produce stable films by physical cross-linking achieved via electrostatic and/or hydrogen bonding interaction has been investigated widely (3)(4)(5)(6)(7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Preparation, Characterization and Evaluation of Antifungal Efficacy of Chitosan/Soy Phosphatidylcholine Topical Films Containing Griseofulvin

Bavarsad

Kouchak

Varmaziar

et al. 2015

Jundishapur J Nat Pharm Prod

View full text Add to dashboard Cite

Background:Griseofulvin is an antifungal drug and is available as oral dosage forms. Development of topical treatment could be advantageous for superficial fungal infections of skin. The film forming property of chitosan has made it interesting for transdermal/ dermal drug delivery, but showed lack of stability. Soy phosphatidylcholine (PC), besides playing penetration enhancer and solubilizer roles, could enhance the stability and mechanical properties of the film. Films prepared from a mixture of chitosan and PC can achieve the benefits of both materials. Objectives: The aim of this study was to prepare and characterize films formed from blends of chitosan and soy PC for topical delivery of griseofulvin. Materials and Methods: Topical films composed of chitosan and soy PC were prepared by means of casting and solvent evaporation technique. The properties of the films were characterized regarding mechanical properties, swelling, ability to transmit vapor, drug release, thermal behavior and antifungal efficacy against Microsporum gypseum and Epidermophyton floccosum. Results: Presence of soy PC improved mechanical properties, lowered swelling ratio and increased stability of the films. Solubilizing activity of phospholipid resulted in higher flux of drug release from formulation containing higher amount of soy PC. Antifungal efficacy of formulations was confirmed against two species of dermatophytes in vitro. Conclusions: This topical composite film had the potential for griseofulvin delivery to superficial fungal infections.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Swelling and Erosionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Preparation, Characterization and Evaluation of Antifungal Efficacy of Chitosan/Soy Phosphatidylcholine Topical Films Containing Griseofulvin

Bavarsad

Kouchak

Varmaziar

et al. 2015

Jundishapur J Nat Pharm Prod

View full text Add to dashboard Cite

show abstract

“…bolus injections of 20 mg kg À1 Taxol s on a q7d Â 3 schedule) or sustained therapy (PTX ePC surgically implanted i.p., providing sustained delivery of 20 mg kg À1 per week) and were compared with controls (drug-free ePC implant). Prior to treatment initiation, release from PTX ePC was confirmed both in vitro and in vivo as described earlier (Grant et al, 2005;Ho et al, 2005;Vassileva et al, 2007). Treatment was initiated 7 days post SKOV3 Luc inoculation, referred to as Day 0; on this date, three mice were killed for visual and microscopic tumour inspection/analysis, and the remainder of the animals (n ¼ 36), were separated into the various groups as described above (n ¼ 12/each group).…”

Section: Treatment Groupsmentioning

confidence: 99%

“…Therefore more tolerable therapeutic interventions are required and in this context, we developed a novel implantable paclitaxel drug delivery system (PTX ePC ). Our initial studies demonstrated that PTX ePC provided local and controlled release of PTX over several weeks and that it was safer and better tolerated than commercially available PTX formulated in Cremophor EL (Grant et al, 2005;Ho et al, 2005;Vassileva et al, 2007).…”

mentioning

confidence: 95%

Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging

et al. 2008

View full text Add to dashboard Cite

We evaluated the pre-clinical efficacy of a novel intraperitoneal (i.p.) sustained-release paclitaxel formulation (PTX ePC ) using bioluminescent imaging (BLI) in the treatment of ovarian cancer. Human ovarian carcinoma cells stably expressing the firefly luciferase gene (SKOV3 Luc ) were injected i.p. into SCID mice. Tumour growth was evaluated during sustained or intermittent courses of i.p. treatment with paclitaxel (PTX). In vitro bioluminescence strongly correlated with cell survival and cytotoxicity. Bioluminescent imaging detected tumours before their macroscopic appearance and strongly correlated with tumour weight and survival. As compared with intermittent therapy with Taxol s , sustained PTX ePC therapy resulted in significant reduction of tumour proliferation, weight and BLI signal intensity, enhanced apoptosis and increased survival times. Our results demonstrate that BLI is a useful tool in the pre-clinical evaluation of therapeutic interventions for ovarian cancer. Moreover, these results provide evidence of enhanced therapeutic efficacy with the sustained PTX ePC implant system, which could potentially translate into successful clinical outcomes.

show abstract

Enhancing Delivery of Small‐Molecule‐ and Cell‐Based Therapies for Ovarian Cancer Using Advanced Delivery Strategies

O’Dwyer

O’Cearbhaill

Wylie

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecological malignancy with a global five‐year survival rate of 30–50%. First‐line treatment involves cytoreductive surgery and administration of platinum‐based small molecules and paclitaxel. These therapies are traditionally administered via intravenous infusion, although intraperitoneal delivery has also been investigated. Initial clinical trials of intraperitoneal administration for ovarian cancer indicate significant improvements in overall survival compared to intravenous delivery, but this result is not consistent across all studies performed. Recently, cell‐based immunotherapy has been of interest for ovarian cancer. Direct intraperitoneal delivery of cell‐based immunotherapies may prompt local immunoregulatory mechanisms to act synergistically with the delivered immunotherapy. Based on this theory, preclinical in vivo studies have delivered these cell‐based immunotherapies via the intraperitoneal route, with promising results. However, successful intraperitoneal delivery of cell‐based immunotherapy and clinical adoption of this technique depend on overcoming challenges of intraperitoneal delivery and finding the optimal combinations of dose, therapeutic, and delivery route. The potential advantages and disadvantages of intraperitoneal delivery of cell‐based immunotherapy for ovarian cancer and the preclinical and clinical work performed so far are reviewed. Potential advanced delivery strategies, which may improve the efficacy and adoption of intraperitoneal delivery of therapy for ovarian cancer, are also outlined.

show abstract

Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel

Cited by 68 publications

References 39 publications

Preparation, Characterization and Evaluation of Antifungal Efficacy of Chitosan/Soy Phosphatidylcholine Topical Films Containing Griseofulvin

Preparation, Characterization and Evaluation of Antifungal Efficacy of Chitosan/Soy Phosphatidylcholine Topical Films Containing Griseofulvin

Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging

Enhancing Delivery of Small‐Molecule‐ and Cell‐Based Therapies for Ovarian Cancer Using Advanced Delivery Strategies

Contact Info

Product

Resources

About